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Background: Axon survival factor nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2) is targeted to Golgi
membranes through palmitoylation, resulting in its rapid turnover and axon degeneration.
Results: Thioesterases APT1/APT2 depalmitoylate NMNAT2 and zDHHC17 is the strongest candidate palmitoyltransferase
for NMNAT2.
Conclusion: Depalmitoylation is insufficient to release NMNAT2 from membranes, suggesting palmitoylation-independent
mechanisms contribute to membrane association.
Significance:Modulation of NMNAT2 subcellular localization could delay axon degeneration in neurodegenerative disease.
The NAD-synthesizing enzyme nicotinamide mononucle-
otide adenylyltransferase 2 (NMNAT2) is a critical survival fac-
tor for axons and its constant supply from neuronal cell bodies
into axons is required for axon survival in primary culture neu-
rites and axon extension in vivo. Recently, we showed that
palmitoylation is necessary to target NMNAT2 to post-Golgi
vesicles, thereby influencing its protein turnover and axon pro-
tective capacity. Here we find that NMNAT2 is a substrate for
cytosolic thioesterases APT1 and APT2 and that palmitoyla-
tion/depalmitoylation dynamics are on a time scale similar to its
short half-life. Interestingly, however, depalmitoylation does
not release NMNAT2 from membranes. The mechanism of
palmitoylation-independent membrane attachment appears to
be mediated by the same minimal domain required for palmi-
toylation itself. Furthermore, we identify several zDHHCpalmi-
toyltransferases that influence NMNAT2 palmitoylation and
subcellular localization, among which a role for zDHHC17
(HIP14) in neuronal NMNAT2 palmitoylation is best supported
by our data. These findings shed light on the enzymatic regula-
tion of NMNAT2 palmitoylation and highlight individual thio-
esterases and palmitoyltransferases as potential targets to mod-
ulate NMNAT2-dependent axon survival.
The NAD-synthesizing enzyme nicotinamide mononucle-
otide adenylyltransferase 2 (NMNAT2)2 is critically required
for axon survival in primary culture neurons (1) and axon
growth and maintenance in vivo (2). As a very short-lived pro-
tein that is transported into axons from the cell body, the half-
life of NMNAT2 limits the duration of survival of a distal axon
stump after its physical separation from the cell body (1). Addi-
tionally, a drop in the supply of NMNAT2 from neuronal cell
bodies into axons could contribute to axon degeneration in
neurodegenerative diseases, where axonal transport has been
shown to be impaired at an early stage (3). In support of this,
expression of amore stable, axonally targetedNMNATenzyme
can rescue axon degeneration and phenotypic disease onset in
animal models of several neurodegenerative conditions includ-
ing motoneuron disease (4), Parkinson disease (5, 6), glaucoma
(7), and myelin-related axon loss (8).
Palmitoylation of a central double-cysteine motif is required
for the association ofNMNAT2withGolgimembranes inHeLa
cells (9, 10) and with axonal transport vesicles in primary cul-
ture neurons (11). In a previous study we found that a small,
central region within the isoform-specific targeting and inter-
action domain (cISTID) of NMNAT2, which contains the
palmitoylated cysteine residues, is sufficient for successful tar-
geting to Golgi membranes and for axonal transport in primary
culture neurons (11). In addition to the palmitoylated cysteines
themselves, a number of basic amino acid residues within the
cISTID region are also required for efficient palmitoylation and
membrane targeting as we found that in their absence
(NMNAT2BR) palmitoylation and membrane targeting are
greatly reduced (11). Furthermore, the palmitoylated cISTID
region is also necessary for association of fluorescently tagged
NMNAT2 with axonal transport vesicles in mouse peripheral
axons in vivo (12). Previously, we reported that its subcellular
localization alters NMNAT2 stability, with membrane binding
resulting in faster turnover due to higher levels of ubiquitina-
tion. In contrast, palmitoylation-deficient, cytosolic mutant
NMNAT2 was more stable and, as a result of its increased half-
life, delayed axon degeneration after cut in mouse primary cul-
ture neurites and Drosophila axons in vivo significantly more
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strongly than wild-type NMNAT2 (11, 12). As palmitoylation
appears to control the subcellular localization ofNMNAT2, it is
important to identify the enzymes and mechanisms that regu-
late NMNAT2 palmitoylation and membrane association.
Palmitoylation is the reversible attachment of palmitic acid
groups to specific cysteine residues in target proteins via thio-
esterase linkages. As a dynamic, post-translational fatty acid
modification it regulates membrane interactions, subcellular
targeting, activity, and turnover of a wide variety of target pro-
teins (13, 14). In neurons specifically, the palmitoylation-de-
pendent subcellular targeting and trafficking of substrate pro-
teins is critical for neuronal function (15–17). The large
zDHHC family of palmitoyltransferasesmediates the palmitoy-
lation of several target proteins, with varying degrees of sub-
strate specificity (18, 19). In contrast, few enzymes are known to
carry out enzymatic depalmitoylation reactions. These include
palmitoyl-protein thioesterase 1 and 2, enzymes thought to
localize to lysosomes and mediate depalmitoylation of sub-
strate proteins prior to lysosomal degradation, and the cytosolic
thioesterases acyl-protein thioesterase 1 and 2 (APT1 and
APT2), which have been shown to depalmitoylate several sub-
strates (20–22) and play roles in palmitate cycling on some
target proteins (23, 24).
Here, we report that thioesterases APT1 and APT2 are both
able to depalmitoylate NMNAT2. Interestingly, however, there
appears to be dissociation betweenNMNAT2depalmitoylation
and membrane detachment, suggesting alternate mechanisms
that mediate stable anchoring of NMNAT2 at membranes.
Within NMNAT2, the cISTID region appears to be sufficient
for this stable, post-palmitoylation membrane attachment.
Additionally, we identify a subset of zDHHC palmitoyltrans-
ferases that are capable of mediating NMNAT2 palmitoyla-
tion and membrane targeting. Among these, zDHHC17
emerges as the strongest candidate for an endogenous role in
regulating levels of NMNAT2 palmitoylation and its subcel-
lular localization.
EXPERIMENTAL PROCEDURES
DNAConstructs—Mouse zDHHC-HA constructs were a gift
from Luke Chamberlain (Glasgow, UK) with kind permission
from Masaki Fukata (Okazaki, Japan). Note that throughout
this paper, palmitoyltransferases are referred to according to
the new standard zDHHC nomenclature. For creation of
EGFP-tagged zDHHC constructs, relevant coding sequences
were transferred to the pEGFP-NI vector (Clontech). Fusions of
wild-type and variantNmnat2with FLAG, EGFP, and photoac-
tivatable GFP (PA-GFP) tags (11) as well as FLAG-WldS and
FLAG-Nmnat1 (1) were described previously. Note that
cISTID-PA-GFP and FLAG-Nmnat2cISTID constructs
were previously referred to as Exon6-PA-GFP and FLAG-
Nmnat2ex6, respectively (11). Table 1 provides an overview of
all NMNAT2 mutants used in this study. FLAG-APT1 and
FLAG-APT2 constructs were generated by PCR amplification
of theAPT1 (NM_008866.2) andAPT2 (NM_011942.1) coding
sequences from a mouse cDNA library and insertion into
pCMV-Tag2A vector (Stratagene). Enzymatically inactive
zDHHC7 (C160S referred to as zDHHS7), zDHHC17 (C467S;
zDHHS17),APT1 (S119A), andAPT2 (S122A) constructs were
created using the QuikChange site-directed mutagenesis kit
(Stratagene) according to the manufacturer’s instructions.
Animals—All animal work was carried out in accordance
with the Animals (Scientific Procedures) Act, 1986, under
Project Licenses 80/2254 and 70/7620. C57BL/6JBabr mice
(BSU, Babraham Institute) were used as a source of wild-type
material.
Primary Neuronal Culture and Photoactivation Imaging—
Dissociated superior cervical ganglia (SCG) cultures were pre-
pared and maintained, and DNA microinjection was carried
out as described previously (11). For photoactivation experi-
ments, 0.03 g/l of Nmnat2-PA-GFP (or variant construct)
were co-injected with 0.01 g/l of mCherry expression vec-
tor and 0.03 g/l of either FLAG-Nmnat1 (control), a
zDHHC-HA expression construct, FLAG-APT1 or FLAG-
APT2 (where both 0.02g/l of FLAG-APT1 and FLAG-APT2
were co-injected). Twenty-four hours after microinjection,
photoactivation imaging was carried out on an Andor Spinning
Disk Confocal System (Nikon 2000E microscope, 100  1.40
NA plan apochromat objective, 488 and 561 nm laser excita-
tion). Where indicated, 50 M palmostatin B (PSB; Cal-
biochem) or 50mMhydroxylamine (HA2; Sigma)were added 30
or 60 min prior to commencement of imaging (see text). The
use of a photoactivatable fluorescent protein fusion to study the
extent of NMNAT2 membrane association was described pre-
viously (11). Briefly, microinjected cell bodies were identified
based on their mCherry fluorescence. PA-GFP fluorescence
was then activated by 10 pulses (20-s pixel dwell time) of a 405
nm laser at 5% intensity in a small 30  30 pixel region of
interest in the cell body. The pool of photoactivated proteinwas
then followed by taking subsequent images at 1 frame/s
(200-ms exposure time) for 3 min. Analysis of protein mobility
was then carried out as described (11).
Co-migration Analysis—Dissociated SCG neurons were
microinjected with 0.03 g/l each of Nmnat2-mCherry and
the indicated zDHHC-EGFP construct. Twenty-four hours
after injection, time lapse imaging of axonal transport and anal-
ysis of co-migration were performed as described previously
(11).
TABLE 1
NMNAT2mutants used in this study
Construct Description Mutations
NMNAT2PS Mutation of palmitoylation site within the cISTID C164S, C165S
NMNAT2BR Mutation of all basic residues within the cISTID
domain
K151A, K155A, R162A, R167A, R172A
cISTID Central portion of the ISTID domain (amino acids
150–177 of full-length NMNAT2)
NAa
NMNAT2cISTID Deletion of the central portion of the ISTID domain 151–177
a NA, non applicable.
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Cell Culture and Palmitate Labeling—HEK 293 cells were
maintained in culture, transfected and labeled with [9,10-
3H]palmitate (PerkinElmer Life Sciences) as described (11).
Where indicated, 50 M PSB was added at the same time as the
radiolabeled palmitate or 5 h after addition of palmitate (i.e. 1 h
before cell lysis). HA (50mM) was added for 60min prior to cell
lysis (i.e. 5 h after addition of radiolabel). Neuroblastoma X
spinal cord cells (NSC34) were maintained in DMEM (Invitro-
gen) supplemented with 10% FBS (Sigma), 1% penicillin/strep-
tomycin (Invitrogen), 2mM L-glutamine (Invitrogen), and 1mM
sodium pyruvate (Invitrogen). NSC34 cells in six-well dishes
were transfected with 4 g of FLAG-Nmnat2 and 1.35 g of
each of the indicated mouse siRNA construct(s) (Thermo Sci-
entific) using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. Seventy-two hours after transfec-
tion, palmitate labeling was carried out as for HEK 293 cells.
EmetineChase andUbiquitination Studies—HEK293 cells in
24-well dishes were transfected with FLAG-WldS and FLAG-
Nmnat2 and subjected to an emetine chase experiment as
described previously (11). Where indicated, 50 M PSB was
added 12 h prior to commencement of the emetine chase. Pull-
down of ubiquitinated FLAG-NMNAT2 using wild-type or
mutantGST-Dsk2UBAconstructs was performed as described
(25, 26).
Western Blotting—SDS-PAGE andWestern blotting analysis
were performed as described (1). The following antibody con-
centrations were used: mouse monoclonal anti-FLAG (Sigma,
M2), 1:3,000; mousemonoclonal anti-GFP (Roche Applied Sci-
ence), 0.1 g/ml; and Alexa Fluor680-conjugated anti-mouse
secondary antibody (Molecular Probes), 1:5,000. Blots were
scanned and quantified using the Odyssey imaging system (LI-
COR Biosciences).
Co-immunoprecipitation—For co-immunoprecipitation
of NMNAT2 and zDHHC palmitoyltransferases, HEK 293
cells grown in 6-well dishes were co-transfected with equal
amounts of FLAG-Nmnat2 (or, where indicated, FLAG-
Nmnat2cISTID) and the relevant zDHHC-EGFP constructs.
24 h after transfection, cells were washed once in PBS and lysed
in 500 l of TG lysis buffer (20 mM Tris, pH 7.5, 137 mM NaCl,
1 mM EGTA, 1% Triton X-100, 10% glycerol, 1.5 mMMgCl2, 50
mM NaF, 1 mM Na3VO4 and protease inhibitor mixture). After
a pre-clearing spin (10 min, 13,000 rpm, 4 °C), 5 g of anti-
FLAG (Sigma, M2) or anti-GFP (Roche) antibody was added to
the supernatant andmixed overnight at 4 °C.The following day,
50 l of 50% washed Protein-G Sepharose beads (Sigma) were
added and the samplewasmixed for 3 h at 4 °C. Beadswere then
applied toMicroSpin columns (Pierce) and washed three times
in TG lysis buffer and twice in wash buffer (50mMTris, pH 8.0).
Protein was eluted in 30 l of Laemmli sample buffer and pro-
cessed for SDS-PAGE and Western blot.
Subcellular Fractionation—Themembrane association assay
was performed as described (27) with modifications. HEK 293
cells in 6-well dishes were transfected with 4 g of FLAG-
Nmnat2 or variant construct, or co-transfected with 2 g each
of FLAG-Nmnat2 and the relevant zDHHC-HA (or empty vec-
tor control) constructs. 24 h after transfection, cells were har-
vested in ice-cold DMEM, washed once in ice-cold PBS, and
resuspended in 400l of buffer 1 (150mMNaCl, 50mMHEPES,
pH 7.4, 24 g/ml of digitonin (Sigma)). After a 10-min end-
over-endmixing at 4 °C, samples were spun for 1min at 5000
g in a bench-top microcentrifuge at 4 °C and the supernatant
was collected as the cytosolic fraction. The pellet was washed
once in ice-cold PBS and resuspended in 400l of buffer 2 (150
mM NaCl, 50 mM HEPES, pH 7.4, 1% IGEPAL CA-630). Com-
plete resuspension was ensured by vortexing samples briefly.
After incubation on ice for 30min, samples were spun for 1min
at 9,000  g in a bench-top microcentrifuge at 4 °C and the
supernatant was collected as the membrane/organelle fraction.
All samples were diluted 1:1 into Laemmli SDS sample buffer
and processed for Western blot. For each sample, the ratio of
FLAG signal in the cytosolic versus membrane fractions was
determined and normalized to control.
Protein Cross-linking—Twenty-four hours after transfection
with 4 g of FLAG-Nmnat2, HEK 293 cells in 6-well dishes
were treated with 50 mM HA for 60 min or with 1 mM dithio-
bis(succinimidyl propionate) for 30 min, followed by 15 min
quenching in 1 M Tris (pH 7.5) and processed for SDS-PAGE.
For reducing conditions, sample buffer contained 5% -mer-
captoethanol and samples were heated to 95 °C for 5 min. For
non-reducing conditions, -mercaptoethanol was omitted
from sample buffer and samples were heated to 80 °C for 3min.
RNA Extraction and qRT-PCR—Total RNA was extracted
from NSC34 cells using TriSure reagent (Bioline), followed by
generation of cDNA using Superscript 2 reverse transcriptase
(Invitrogen), according to the manufacturer’s instructions.
Quantitative RT (qRT)-PCR measurements of zDHHC7 and
zDHHC17mRNAabundancewere performed on aRotor-Gene
Q Model 2-Plex HRM cycler running Rotor-Gene Q Software
version 2.3.1 (Qiagen) and quantified using the (Ct) method
by reference to Actb and Gusb. The following primers were
used: zDHHC7 (forward, gagaaccatgctcactgacc; reverse, gc-
acttgtagatcacctcgc; expected amplicon mRNA: 103 bp,
genomic: 1103 bp), zDHHC 17 (forward, gtttcacttcctgtgg-
gtgg; reverse, gcttgtatctcctggcgttc; expected amplicon
mRNA: 103 bp, genomic: 707 bp), Actb (forward, tgaaccc-
taaggccaaccgt; reverse, aggcatacagggacagcaca; expected
amplicon mRNA: 104 bp, genomic: 560 bp), Gusb (forward,
gttgaggatcaacagtgccc; reverse, atgtcagcctcaaaggggag; ex-
pected amplicon size mRNA: 98 bp, genomic: 313 bp). The
presence of a single amplicon in each reaction was confirmed
by melt curve analysis and agarose gel electrophoresis after
completion of the qRT-PCR cycle.
RESULTS
NMNAT2 Is a Substrate for Thioesterases APT1 and APT2—
We previously reported that the cISTID of NMNAT2 is neces-
sary and sufficient for membrane targeting and that, within the
cISTID region, a double cysteinemotif and several surrounding
basic residues are necessary for efficient palmitoylation and
membrane binding (11). Deletion of the entire cISTID region or
specific mutation of the palmitoylated cysteine residues within
the cISTID abolish NMNAT2 palmitoylation and result in a
diffuse, cytosolic distribution of the mutant proteins (11). Pho-
toactivation of fluorescently tagged NMNAT2 variants in SCG
neurons (see “Experimental Procedures”) illustrates that wild-
type NMNAT2 tagged to PA-GFP is strongly membrane
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bound, with most of the fluorescence signal remaining in the
originally activated area of the cell body (Fig. 1, A and B). In
contrast, NMNAT2BR, in which basic residues surrounding
the Cys164–165 palmitoylation site within the cISTID region are
mutated (11), shows a much more diffuse localization, with
most of the fluorescence signal spreading throughout the cell
body and only a small fraction remaining within the originally
activated area (Fig. 1,A andB; see Table 1 for an overview of the
properties of all NMNAT2 mutant constructs used). Impor-
tantly, NMNAT2BR is still palmitoylated (albeit to a much
lesser extent than wild-type NMNAT2) and, like wild-type
NMNAT2, a portion of it is targeted toGolgi membranes in the
cell body andGolgi-derived axonal transport vesicles (although
a partial association with the ER in cell bodies cannot be
excluded) (11). The strong reduction in membrane association
relative to wild-type NMNAT2 means that NMNAT2BR is a
useful tool to study potential increases inNMNAT2membrane
binding.
To test whether NMNAT2 can undergo depalmitoylation
mediated by the cytosolic thioesterasesAPT1 orAPT2, we used
PSB, an inhibitor of APT1 and APT2 thioesterase activity (23,
28). PSB (50 M) was applied to SCG neurons for 30 or 60 min
prior to imaging and led to a significant increase in membrane
association of NMNAT2BR-PA-GFP (Fig. 1, A and B). This
suggests that a PSB-sensitive thioesterase activity limits the
extent of NMNAT2BRmembrane association and that depal-
mitoylation by thioesterases is a necessary step for the release of
NMNAT2 from membranes. The fact that PSB treatment
affected the subcellular localization of NMNAT2BR on rela-
tively short time scales suggests that depalmitoylation could
influence the localization and turnover of endogenous
NMNAT2, which has a half-life of less than 1 h (11). Using
[3H]palmitate labeling in HEK 293 cells, we found that PSB
treatment significantly boosted the steady-state incorporation
of labeled palmitate into FLAG-NMNAT2, independently of
whether it was applied for the whole labeling period or only
during the last hour of [3H]palmitate labeling (Fig. 1, C and D).
Although technical constraints mean that we were not able to
directly measure the rate of [3H]palmitate incorporation into
NMNAT2 in SCG neurons, our findings nevertheless, indicate
that the effects of PSB treatment are qualitatively similar in
both cell types, and that the above effects of PSB on membrane
FIGURE 1. Palmostatin B treatment boosts NMNAT2membrane association and palmitoylation. A, individual frames from photoactivation assay of SCG
primary culture neurons expressing NMNAT2-PA-GFP or NMNAT2BR-PA-GFP. APT inhibitor PSB (50 M) or DMSO (control) were added to NMNAT2BR-PA-
GFP expressing cells 30 or 60min prior to imaging. The region of activation is indicated by an orange circle in each image. B, quantification of proteinmobility
in A. Error bars indicate S.E., n 3 independent experiments. Protein mobility of NMNAT2BR was significantly decreased by addition of PSB (**, p 0.001,
non-linear curve fit). C, [3H]palmitate label andWestern blots of FLAG-NMNAT2. HEK 293 cells expressing FLAG-NMNAT2were labeledwith [3H]palmitatewith
50 M PSB present (PSB) during the last hour of palmitate labeling (top) or throughout the labeling period (6 h, bottom) and subjected to FLAG-immunopre-
cipitation and processed for PhosphorImaging and Western blot. Note that an intervening band has been cropped out of the top blot (1 h PSB) but that
brightness and contrast settings are identical between bands. D, quantification of palmitate incorporation. As there was no statistically significant difference
between samples treated with PSB for 1 or 6 h, values were combined for analysis. Intensity of detected radiolabel was normalized to the FLAG signal on
Western blot for each condition. For presentation, values were normalized to control. Error bars indicate S.E., n  4 independent experiments. *, indicates
statistically significant difference compared with control (*, p 0.05; paired t test).
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association are mediated through effects on NMNAT2
palmitoylation.
Next, we sought to confirm that the effects of PSB treatment
on NMNAT2 palmitoylation were indeed mediated by APT1
and/or APT2. Co-overexpression of NMNAT2-EGFP with
FLAG-APT1 and/or FLAG-APT2 significantly reduced the
incorporation of [3H]palmitate intoNMNAT2-EGFP to similar
extents (Fig. 2, A and E), despite the observation that FLAG-
APT2 was expressed at significantly higher levels than FLAG-
APT1 in this assay (Fig. 2B). To test whether the thioesterase
activities of APT1 and APT2 were required for their effect
on [3H]palmitate incorporation into NMNAT2, we created
enzyme-dead variants of both thioesterases based on previously
published findings (29, 30). Co-overexpression of FLAG-
APT1S119A or FLAG-APT2S122A did not alter palmitate incor-
poration into NMNAT2-EGFP (Fig. 2,C and E). However, it is
worth noting that the enzyme-dead variant of FLAG-APT2was
expressed at significantly lower levels than the wild-type in this
assay (Fig. 2D). Nevertheless, these results suggest that APT1
andAPT2 are both able to efficiently depalmitoylate NMNAT2
under these conditions and that their thioesterase activities are
required for this effect.
Depalmitoylation Is Insufficient for NMNAT2 Membrane
Detachment—Based on the above results, we hypothesized that
depalmitoylation of NMNAT2 by APT1 and APT2 could
release NMNAT2 from membranes. To test this idea, we co-
overexpressed NMNAT2-PA-GFP or NMNAT2BR-PA-GFP
together with FLAG-APT1 or FLAG-APT2. Interestingly, nei-
ther APT1 nor APT2 were able to release NMNAT2 from
membranes (Fig. 3). Moreover, even combined overexpression
of FLAG-APT1 and FLAG-APT2 had no effect on the mem-
brane retention of NMNAT2 or NMNAT2BR (Fig. 4). Given
that overexpression of APT1 and APT2 only reduced
[3H]palmitate incorporation into NMNAT2 by around 60%
(Fig. 2E), it is possible that more complete depalmitoylation by
APT1 and APT2, or by other thioesterases, is required to suc-
cessfully release NMNAT2 from membranes. However, an
interesting alternative is the possibility that depalmitoylation is
not sufficient to release NMNAT2 frommembranes and that
other mechanisms could maintain stable anchoring of
NMNAT2. Thus, we aimed to define the sequence require-
ments of NMNAT2 for this potential post-palmitoylation
membrane anchoring mechanism.
We found that a cISTID-PA-GFP construct, which we previ-
ously showed to be necessary and sufficient for NMNAT2
membrane targeting (11)was also retained atmembranes in the
presence of APT1 and APT2 (Fig. 4). This suggests that the
putative alternative mechanism of membrane association that
allows NMNAT2 to remain membrane bound in the presence
of overexpressed APT1 and APT2 is mediated by sequences
within the cISTID region, but does not require the basic resi-
dues mutated in NMNAT2BR. Together, our data suggest
that boosting levels of NMNAT2 palmitoylation through PSB
treatment can drive more of the protein to membranes (Fig. 1),
but a decrease of palmitoylation levels by overexpression of
APT1 and/or APT2 is not sufficient to increase its rate ofmem-
brane dissociation (Figs. 3 and 4).
To further confirm that NMNAT2 can remain membrane
associated following depalmitoylation, we used the thiol-reac-
tive compound HA for chemical depalmitoylation. HA treat-
FIGURE 2. APT1 and APT2 overexpression reduce NMNAT2 palmitoylation.
A, [3H]palmitate labeling and Western blot of NMNAT2-EGFP. HEK 293 cells
expressing NMNAT2-EGFP together with FLAG-NMNAT1 (control), FLAG-APT1
(APT1), FLAG-APT2 (APT2), orFLAG-APT1andFLAG-APT2 (APT12)were labeled
with [3H]palmitate, subjected to EGFP immunoprecipitation and processed for
PhosphorImagingandWesternblot.All imagesareof thesamegelwiththesame
corrections (brightness and contrast) applied but with an intervening lane
cropped out. B, input samples from A showing expression of FLAG-NMNAT1
(control), FLAG-APT1, and/or FLAG-APT2 as indicated. C, [3H]palmitate labeling
and Western blot of NMNAT2-EGFP. HEK 293 cells expressing NMNAT2-EGFP
together with FLAG-NMNAT1 (control), enzyme-dead FLAG-APT1S119A (APT1d),
or enzyme-dead FLAG-APT2S122A (APT2d) were labeled with [3H]palmitate, sub-
jected to EGFP immunoprecipitation, and processed for PhosphorImaging and
Western blot. D, input samples from C showing expression of FLAG-NMNAT1
(control), FLAG-APT1S119A (APT1d), or FLAG-APT2S122A (APT2d) as indicated. E,
quantification of palmitate incorporation. Intensity of detected radiolabel was
normalized to EGFP signal onWestern blot for each condition. For presentation,
values were normalized to control. Error bars indicate S.E., n  3 independent
experiments. *, indicates statistically significant difference compared with con-
trol (*, p 0.05; **, p 0.01; one-way analysis of variance with Tukey’s Multiple
Comparisons post-test).
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ment (50 mM, 60 min) significantly reduced the incorporation
of [3H]palmitate into FLAG-NMNAT2 inHEK 293 cells (Fig. 5,
A and B). The same treatment, however, did not alter themem-
brane association status of NMNAT2-PA-GFP or cISTID-PA-
GFP (Fig. 5,D and E). To account for potential off-target effects
of HA on cells in this assay, we confirmed that HA treatment
did not induce detectable protein cross-linking under these
conditions, whereas dithiobis(succinimidyl propionate), a
known cross-linking agent containing a disulfide bond, caused
a significant accumulation of high molecular weight species
that was sensitive to reducing conditions on SDS-PAGE (Fig.
5C). Moreover, we excluded a nonspecific effect of HA treat-
FIGURE 3.Overexpression of APT1 or APT2 does not release NMNAT2 frommembranes. A, individual frames from photoactivation assay of SCG primary
culture neurons expressing NMNAT2-PA-GFP or NMNAT2BR-PA-GFP together with FLAG-NMNAT1 (control), FLAG-APT1 or FLAG-APT2. The region of activa-
tion is indicated by an orange circle in each image. B, quantification of protein mobility in A. Error bars indicate S.E., n 3 independent experiments. Protein
mobility of NMNAT2-PA-GFP or NMNAT2BR-PA-GFP was not altered significantly by presence of FLAG-APT1 or FLAG-APT2 (p 0.05; non-linear curve fit).
FIGURE 4. Combined overexpression of APT1 and APT2 does not release NMNAT2 frommembranes. A, individual frames from photoactivation assay of
SCG primary culture neurons expressing NMNAT2-PA-GFP, NMNAT2BR-PA-GFP, or cISTID-PA-GFP together with FLAG-NMNAT1 (control) or FLAG-APT1 and
FLAG-APT2. The region of activation is indicated by an orange circle in each image. B, quantification of protein mobility in A. Error bars indicate S.E., n  3
independent experiments. Protein mobility was not altered significantly by the presence of FLAG-APT1 and FLAG-APT2 in any of the conditions (p  0.05;
non-linear curve fit).
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ment on proteinmobility by confirming that themobility of the
cytosolic NMNAT2cISTID mutant was not affected by HA
exposure (Fig. 5, D and E). Together, these data suggest the
existence of a palmitoylation-independentmechanismof stable
membrane association for NMNAT2 mediated by the cISTID
region.
Depalmitoylation Does Not Affect NMNAT2 Ubiquitination
and Turnover—Given our previous results regarding the local-
ization dependence of NMNAT2 ubiquitination and turnover
(11), we thought it interesting to ask whether the rate of
NMNAT2 depalmitoylation by APT1 and APT2 affects its
ubiquitination or turnover. To this end, we performed emetine
chase experiments in HEK 293 cells to determine the rate of
turnover of FLAG-NMNAT2. Interestingly, we found that inhi-
bition of APT1 and APT2 with PSB did not affect the rate of
NMNAT2 turnover in these cells (Fig. 6,A andB). Similarly, we
found no evidence for altered levels of ubiquitination of FLAG-
NMNAT2 after PSB treatment in ubiquitin pull-down experi-
ments (Fig. 6C). This observation is consistent with the above
findings indicating a dissociation between NMNAT2 depalmi-
toylation and membrane dissociation as our previous results
suggested that membrane association, rather than palmitoyla-
tion status, determines NMNAT2 ubiquitination and its rate of
turnover (11).
A Subset of zDHHC Proteins Are Candidate Palmitoyltrans-
ferases for NMNAT2—Next, we aimed to identify palmitoyl-
transferase enzymes that could mediate NMNAT2 palmitoyla-
tion. In an initial screen, we assayed the ability of 23 mouse
zDHHC family palmitoyltransferases to boost membrane tar-
geting of FLAG-NMNAT2when co-overexpressed in HEK 293
cells using a subcellular fractionation method previously used
to identify candidate zDHHC enzymes for other substrates (31,
32). We identified six candidate zDHHC enzymes that signifi-
cantly increased NMNAT2membrane association in this assay
(Fig. 7,A andC). It is important to note that expression levels
of individual zDHHC enzymes in this assay varied consider-
ably (Fig. 7B). However, there was no correlation between
the expression levels of individual zDHHC enzymes and
their ability to increase membrane association of NMNAT2
in this assay (e.g. compare zDHHC 17 and zDHHC9 in Fig. 7,
B and C). Interestingly, a few of the zDHHC enzymes
appeared to reduce NMNAT2 membrane association. This
FIGURE 5.Chemical depalmitoylation does not release NMNAT2 frommembranes. A, [3H]palmitate labeling andWestern blot of FLAG-NMNAT2. HEK 293
cells expressing FLAG-NMNAT2were labeledwith [3H]palmitate for a total of 6 h, in the absence (control) or presence (HA) of 50mMhydroxylamine (HA) during
the final hour of incubation. Following lysis, samples were subjected to FLAG immunoprecipitation and processed for PhosphorImaging andWestern blot. B,
quantification of palmitate incorporation. Intensity of the detected radiolabel was normalized to the FLAG signal on Western blots for each condition. For
presentation, values of the HA-treated samples was normalized to control. Error bars indicate S.E., n  3 independent experiments. *, indicates statistically
significant difference compared with control (*, p 0.05; t test). C,Western blot of FLAG-NMNAT2. HEK 293 cells expressing FLAG-NMNAT2were treated with
50 mM HA for 1 h or with 1 mM dithiobis(succinimidyl propionate) for 30 min and separated by reducing (5% -mercaptoethanol, -ME) or non-reducing
SDS-PAGE.D, individual frames fromphotoactivation assay of SCG primary culture neurons expressing NMNAT2-PA-GFP (top) or cISTID-PA-GFP (bottom) after
incubation for 1 h in the absence (control) or presence (HA) of 50mMHA. The region of activation is indicatedby an orange circle in each image. E,quantification
of protein mobility in the presence and absence of HA. Error bars indicate S.E., n  3–4 independent experiments. Protein mobility of NMNAT2-PA-GFP,
cISTID-PA-GFP, or NMNAT2cISTID-PA-GFP was not altered significantly by treatment with HA (p 0.05; non-linear curve fit).
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observation is consistent with previous studies using this
technique (31) but the underlying mechanism of this sup-
pression of membrane association is currently unknown.
However, zDHHC 13 and zDHHC25 were previously shown
to suppress incorporation of [3H]palmitate into PDE10A
(33) so the reduction in NMNAT2 membrane association by
zDHHC4 and zDHHC25 observed here could indeed repre-
sent a reduction in NMNAT2 palmitoylation.
To confirm that the observed increases in NMNAT2 mem-
brane association in the presence of candidate zDHHC
enzymes were due to increased levels of NMNAT2 palmitoyla-
tion, we performed [3H]palmitate labeling of FLAG-NMNAT2
in HEK 293 cells co-overexpressing individual zDHHC en-
zymes. As predicted, incorporation of [3H]palmitate into
FLAG-NMNAT2 was significantly increased by all six candi-
date zDHHC enzymes (Fig. 8, A and C) but not by a zDHHC
enzyme that did not alter membrane association of NMNAT2
in the subcellular fractionation assay above (zDHHC18).
To further support an enzyme-substrate interaction between
the candidate zDHHC enzymes and NMNAT2, we performed
co-immunoprecipitation assays as enzyme-substrate com-
plexes have been demonstrated for several zDHHC-substrate
pairings (34–36). We found that all candidate zDHHC-EGFP
constructs, but not EGFP alone, or zDHHC9, which did not
alter NMNAT2 membrane association, were significantly
enriched in FLAG immunoprecipitation in the presence of
FLAG-NMNAT2 but not in its absence (Fig. 9A). Conversely,
FLAG-NMNAT2 was significantly co-immunoprecipitated
by all zDHHC candidates, but not by EGFP alone or by
zDHHC9 (Fig. 9B). Although expression levels vary consid-
erably between zDHHC enzymes in this assay (see Fig. 7B),
there is no correlation between the relative expression levels
of zDHHC enzymes and the extent of their co-immunopre-
cipitation with NMNAT2, suggesting that these are specific,
expression level independent effects. For interaction with
most candidate zDHHC enzymes, the cISTID region of
NMNAT2 appears to be required, as a cISTID-deficient
FLAG-NMNAT2cISTID did not co-immunoprecipitate
candidate zDHHC enzymes (Fig. 9A) and was not co-immu-
noprecipitated by candidate zDHHC enzymes (Fig. 9C).
Interestingly, however, zDHHC17 and zDHHC21 appear to
be an exception to this, as we observed a bidirectional
co-immunoprecipitation of these zDHHCs and FLAG-
NMNAT2cISTID (Fig. 9, A and C, arrows). This suggests
that the interactions between NMNAT2 and zDHHC17 or
zDHHC21 are partially mediated by regions outside of the
minimum cISTID region of NMNAT2 that is required for
palmitoylation. For zDHHC17, this observation is in agree-
ment with reports for other substrates for which sequences
outside of the minimum palmitoylation domain of the sub-
strate have been shown to interact with the zDHHC17
palmitoyltransferase (34, 37).
FIGURE 6. Palmostatin B treatment does not affect NMNAT2 turnover or ubiquitination. A, representative Western blots of HEK 293 cells co-transfected
with FLAG-WldS and FLAG-Nmnat2 andmaintained in the presence (PSB, 50M) or absence (control) of PSB. 24 h after transfection, cells were treated with 10
M emetine for the amount of time indicated after which samples were processed for SDS-PAGE andWestern blot using anti-FLAG antibody. B, quantification
of NMNAT2 turnover after emetine treatment in the presence or absence of PSB. For each sample and time point the amount of FLAG-NMNAT2 remainingwas
normalized to FLAG-WLDS as an internal control. Error bars indicate S.E., n 3 independent experiments. Half-lives were not significantly different (p 0.66;
non-linear curve fit) and the orange line indicates the shared, fitted exponential decay curve. C, representativeWestern blots of GST-DSK2 pulldown assay. HEK
293 cells expressing FLAG-NMNAT2weremaintained in the presence (PSB, 50M) or absence (control) of PSB. Six hours prior to lysis, freshmedium containing
MG-132 (left) or control medium without MG-132 (right) was added. Cells were lysed (inp., total input) and ubiquitinated proteins were immunoprecipitated
using GST-DSK2 bound to glutathione beads (ubiq.). GST-fused mutant DSK2 was used for control pulldown (cont.). Eluted proteins were processed for
SDS-PAGE and analyzed by Western blot using anti-FLAG antibody.
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FIGURE 7. Candidate zDHHC palmitoyltransferases increase NMNAT2 membrane association. A, representative Western blots of NMNAT2 membrane
association assay. HEK 293 cells expressing FLAG-NMNAT2 (wt), FLAG-NMNAT2BR (BR), FLAG-NMNAT2PS (PS), or co-expressing FLAG-NMNAT2 and
empty vector (control) or one of 23 zDHHC-HA constructswere subjected to a simple subcellular fractionationprotocol to separate cytosolic (c) andmembrane
(m) fractions and processed for SDS-PAGE andWestern blot using anti-FLAG antibody. Note that an intervening lane has been cropped out in the second from
top blot. B,Western blot of input samples from A showing expression of HA-tagged zDHHCs.Where only faint bands are visible due to exposure settings, these
are indicated by arrows. C, quantification of FLAG-NMNAT2 membrane-to-cytosol ratio in presence of empty vector (control) or expression of one of the
zDHHC-HA enzymes. For presentation, values were normalized to control. Error bars indicate S.E., n  4 independent experiments. *, indicates statistically
significant difference comparedwith control (*,p 0.05; **,p 0.01; ***,p 0.001; one-way analysis of variancewith Tukey’smultiple comparisons post-test).
FIGURE 8. Overexpression of candidate zDHHC enzymes boosts NMNAT2 palmitoylation. A and B, [3H]palmitate labeling and Western blot of FLAG-
NMNAT2. HEK 293 cells expressing FLAG-NMNAT2 only (control) or FLAG-NMNAT2 together with the indicated zDHHC-HA (A) or an enzyme-dead zDHHS-HA
mutant (B) were labeled with [3H]palmitate, subjected to FLAG immunoprecipitation, and processed for PhosphorImaging and Western blot. C and D,
quantification of palmitate incorporation in A and B, respectively. Intensity of detected radiolabel was normalized to FLAG signal on Western blot for each
condition. For presentation, values were normalized to control. Error bars indicate S.E., n  3 independent experiments. *, indicate statistically significant
difference compared with control (*, p  0.05; **, p  0.01; ***, p  0.001; one-way analysis of variance with Tukey’s multiple comparisons post-test). E,
[3H]palmitate labeling and Western blot of FLAG-NMNAT2PS. HEK 293 cells expressing FLAG-NMNAT2 PS only (control) or FLAG-NMNAT2 together with
zDHHC7 or zDHHC17 were labeled with [3H]palmitate, subjected to FLAG immunoprecipitation, and processed for PhosphorImaging and Western blot
analysis.
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To confirm the observations from themembrane association
assay in neuronal cells, we determined the membrane associa-
tion of NMNAT2BR in the presence of individual candidate
zDHHC enzymes using the photoactivation assay in SCG cell
bodies. Co-expression of zDHHC2, zDHHC15, zDHHC16, and
zDHHC21 had modest, statistically non-significant effects on
the membrane association of NMNAT2BR-PA-GFP (Fig. 10,
A and B). In contrast, zDHHC7 and zDHHC17 both led to sta-
tistically significant increases in membrane retention of
NMNAT2BR-PA-GFP (Fig. 10, A and B). These findings sug-
gest zDHHC7 and zDHHC17 as the strongest candidates for
zDHHC palmitoyltransferases that affect the subcellular local-
ization of NMNAT2 in neurons.
Given the potential roles of zDHHC7 and zDHHC17 in
mediatingNMNAT2palmitoylation, we sought to confirm that
their observed effects on NMNAT2membrane association and
palmitoylation were dependent on their enzyme activities.
We found that enzyme-dead zDHHC7C160S (referred to as
zDHHS7) and zDHHC17C467S (zDHHS17) did not promote
[3H]palmitate incorporation into FLAG-NMNAT2 (Fig. 8, B
and D). Accordingly, overexpression of zDHHS7 or zDHHS17
did not affect the membrane targeting of NMNAT2BR in the
photoactivation assay (Fig. 10C). Moreover, we sought to
confirm the requirement for the Cys164/Cys165 palmitoylation
site in NMNAT2 by demonstrating that overexpression of
zDHHC7 or zDHHC17 did not lead to an increase in
[3H]palmitate incorporation into NMNAT2PS (Fig. 8E), or to
an increase in its membrane association in the photoactivation
assay (Fig. 10C). Together, these results indicate that zDHHC7
and zDHHC17 affect NMNAT2 palmitoylation and subcellular
localization through mechanisms that require intact palmitoy-
lation sites in both the enzymes and the substrate.
Endogenous zDHHC17 Affects NMNAT2 Palmitoylation—
Although the above results establish zDHHC7 and
zDHHC17 as candidate zDHHC palmitoyltransferases with
an influence on NMNAT2 subcellular localization in neu-
rons, they were based on overexpression of both NMNAT2
and the zDHHC enzyme. To test whether endogenous
zDHHC7 or zDHHC17 are involved in NMNAT2 palmitoy-
lation, we utilized an siRNA approach in the neuronal
NSC34 cell line. We used qRT-PCR to confirm mRNA level
expressions of zDHHC7 and zDHHC17 in this cell line and to
test the efficiency of knock-down achieved by the siRNA.We
found that both zDHHC candidates were expressed and that
their mRNA expression levels were incompletely but signif-
icantly attenuated by the relevant siRNA treatment. Knock-
down of zDHHC7 was slightly more efficient than knock-
down of zDHHC17, especially when both siRNAs were used
in combination (Fig. 11, C and D). Although siRNA-
mediated knockdown of zDHHC7 did not significantly affect
[3H]palmitate incorporation into FLAG-NMNAT2 at 3 days
post-transfection. In contrast, knockdown of zDHHC17,
even though less complete than that of zDHHC7 at mRNA
level, reduced [3H]palmitate labeling of FLAG-NMNAT2 by
40%, regardless of whether zDHHC7 was knocked down at
the same time or not (Fig. 11, A and B). The observed incom-
plete suppression of [3H]palmitate incorporation could be
the result of incomplete knockdown of zDHHC17 itself
(see Fig. 11D) and/or the activity of alternative zDHHC
enzymes partially compensating for the reduction in
zDHHC17 levels. Nevertheless, our results strongly suggest a
role for endogenous zDHHC17 in NMNAT2 palmitoylation
in these cells.
FIGURE 9. Co-immunoprecipitation of NMNAT2 and candidate zDHHC palmitoyltransferases. A, representative Western blots of zDHHC-EGFP
palmitoyltransferases co-immunoprecipitated with wild-type or mutant FLAG-NMNAT2. HEK 293 cells expressing candidate zDHHC-EGFP constructs
together with an empty vector control (top row), FLAG-NMNAT2 (middle row) ormutant FLAG-NMNAT2cISTID (bottom row) were lysed (inp, total input),
subjected to immunoprecipitation using anti-FLAG antibody (IP), and processed for SDS-PAGE and Western blot (WB) analysis using anti-GFP antibody.
B and C, representative Western blots of wild-type or mutant FLAG-NMNAT2 co-immunoprecipitated with zDHHC-EGFP palmitoyltransferases. HEK 293
cells expressing FLAG-NMNAT2 (B) or FLAG-NMNAT2cISTID (C) together with untagged EGFP control or candidate zDHHC-EGFP constructs were lysed
(inp, total input), subjected to immunoprecipitation using anti-GFP antibody (IP) and processed for SDS-PAGE and Western blot using anti-GFP and
anti-FLAG antibodies. Apparent molecular masses of tagged proteins onWestern blots were as follows: FLAG-NMNAT2, 34 kDa; FLAG-NMNAT2cISTID,
30 kDa; EGFP, 26 kDa; zDHHC2-EGFP, 65 kDa; zDHHC7-EGFP, 50 kDa; zDHHC9-EGFP, 65 kDa; zDHHC15-EGFP, 68 kDa; zDHHC16-EGFP, 68 kDa; zDHHC17-
EGFP, 100 kDa; zDHHC21-EGFP, 45 kDa.
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FIGURE 10.Overexpression of candidate zDHHC palmitoyltransferases increases NMNAT2membrane association. A, individual frames from photoac-
tivation assay of SCG primary culture neurons expressing NMNAT2BR-PA-GFP or co-expressing NMNAT2BR-PA-GFP and candidate zDHHC-HA constructs.
The region of activation is indicated by an orange circle in each image. B, quantification of protein mobility in A. Error bars indicate S.E., n 3 independent
experiments. *, indicates statistically significant difference compared with NMNAT2BR-PA-GFP control (n.s., non-significant; ***, p 0.001; non-linear curve
fit). C, quantification of protein mobility in photoactivation assay. Mobility of NMNAT2BR-PA-GFP was not altered significantly by co-expression of enzyme-
dead zDHHS7 or zDHHS17 and mobility of NMNAT2PS-PA-GFP was not affected by co-expression of zDHHC7 or zDHHC17. Error bars indicate S.E., n  3
independent experiments.
FIGURE 11. Endogenous zDHHC17 contributes to NMNAT2 palmitoylation in NSC34 cells. A, [3H]palmitate labeling and Western blot of FLAG-NMNAT2.
NSC34 cells transfected with FLAG-Nmnat2 together with non-targeting siRNA control (n.t.) or siRNA against zDHHC7 and/or zDHHC17 as indicated were
labeled with [3H]palmitate, subjected to FLAG-immunoprecipitation, and processed for PhosphorImaging and Western blot. B, quantification of palmitate
incorporation. Intensity of detected radiolabelwasnormalized to the FLAGsignal onWesternblot for each condition. For presentation, valueswerenormalized
to control. Error bars indicate S.E.,n4 independent experiments. *, indicates statistically significant difference comparedwith control (*,p0.05; **,p0.01;
one-way analysis of variance with Tukey’s multiple comparisons post-test). C, quantification of siRNA knockdown efficiency of zDHHC7 mRNA. qRT-PCR
measurements of zDHHC7mRNA abundancewere quantified relative to Actb andGusb and normalized to control (n.t., non-targeting siRNA control). Error bars
indicate S.E., n 3 independent experiments.D, quantification of siRNA knockdown efficiency of zDHHC17mRNA. qRT-PCRmeasurements of zDHHC17mRNA
abundance were quantified relative to Actb and Gusb and normalized to control (n.t., non-targeting siRNA control). Error bars indicate S.E., n 3 independent
experiments.
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DISCUSSION
In this study, we identify a set of palmitoyltransferase and
thioesterase enzymes that appear to regulate NMNAT2 palmi-
toylation levels and its subcellular localization. Interestingly,
however, there appears to be some dissociation between palmi-
toylation andmembrane attachment, suggesting that palmitoy-
lation could play roles beyond the regulation of NMNAT2 sub-
cellular localization.
Whereas previous studies reported substrate specificity in
the depalmitoylation of target proteins by either APT1 (20, 38)
or APT2 (21), NMNAT2 appears to be equally susceptible to
depalmitoylation by both of these thioesterases. Similarly, a
semi-synthetic N-Ras protein was also depalmitoylated by both
APT1 andAPT2 in vitro (28), but, to our knowledge, our results
are the first suggestion of a protein substrate for bothAPT1 and
APT2 in living cells.
Our results indicate that NMNAT2 membrane association
can be maintained following depalmitoylation. However, for
NMNAT2 to eventually dissociate from membranes, depalmi-
toylation likely remains a necessary step as inhibition of thioes-
terase activity by PSB led to increasedmembrane association of
NMNAT2BR. The observation that membrane association of
NMNAT2 ismaintained following depalmitoylation is in agree-
ment with findings for other palmitoylated proteins including
GAP-43 (39) and SNAP-25 (40). For NMNAT2, the cISTID
region is sufficient to mediate this post-palmitoylation mem-
brane attachment but basic residues within this region are not
required. Thus, this mechanism of membrane association
appears to be different from the initial membrane targeting
mediated by cISTID basic residues that is necessary for efficient
palmitoylation to occur in the first place (11). Although the
precise mechanism behind this continued membrane associa-
tion of depalmitoylated NMNAT2 remains to be elucidated, it
is interesting to note that it requires palmitoylation to be estab-
lished first, suggesting amultistep process ofmembrane target-
ing and stable association.
It is interesting to note that the set of zDHHC enzymes we
identified as candidates for mediating palmitoylation of
NMNAT2 (zDHHC2, -7, -15, -16, -17, and -21) shows extensive
overlap with the series of zDHHC palmitoyltransferases found
to promote palmitoylation of SCG10/stathmin2 (zDHHC2, -3,
-7, -15, -17, and -21) (36). Both, NMNAT2 and SCG10, are
labile, palmitoylated proteins that play important roles in axon
survival and in determining the duration of the latent phase of
Wallerian degeneration (1, 2, 41), so it is intriguing to speculate
that their regulation by a similar group of zDHHC palmitoyl-
transferases could be functionally important for axon survival
and the course of Wallerian degeneration.
The evidence presented here suggests that endogenous
zDHHC17 is involved in the palmitoylation of NMNAT2.
Using overexpression and knockdown approaches, our findings
indicate that modulation of zDHHC17 levels is sufficient to
alter the extent of NMNAT2 palmitoylation as well as its sub-
cellular localization. zDHHC17 was found to palmitoylate a
variety of target proteins (42), including huntingtin (43). More-
over, palmitoylation of a zDHHC17 target protein, as well as
palmitoylation of zDHHC17 itself, were found to be impaired in
a mouse model of Huntington disease (44) and loss of
zDHHC17 inmice produces a phenotype that recapitulates sev-
eral features of Huntington disease (44, 45), indicating that
a failure to maintain proper palmitoylation dynamics of
zDHHC17 target proteins could be one of the pathological fea-
tures in Huntington disease. Given the role of NMNAT2 in
axon survival (1, 2), the finding that zDHHC17 could regulate
NMNAT2 palmitoylation suggests a potential impairment of
NMNAT2 palmitoylation and subcellular targeting in Hun-
tington disease models that warrants further investigation.
Further work is required to elucidate the functional effects of
each of the enzymes identified here in regulating NMNAT2-
mediated axon survival. However, given previous findings
regarding the role of NMNAT2 subcellular localization and the
duration of axon survival after axotomy, targeting the enzymes
identified here might provide novel avenues to delay axon
degeneration throughmodulation of NMNAT2 palmitoylation
and subcellular localization.
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